Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Sign Up to like & getrecommendations! Published in 2017 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000398
Abstract: BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAFV600E-mutated melanoma. The results of a descriptive study evaluating vemurafenib… read more here.
Keywords: melanoma; mutations v600e; braf; braf mutations ... See more keywords